BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18508192)

  • 1. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
    Wang S; Yang Q; Fung KM; Lin HK
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):60-6. PubMed ID: 18508192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
    Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
    BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
    Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
    Mantel A; Newsome A; Thekkudan T; Frazier R; Katdare M
    Exp Dermatol; 2016 Jan; 25(1):38-43. PubMed ID: 26308156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
    Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
    Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
    Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
    Ji Q; Chang L; VanDenBerg D; Stanczyk FZ; Stolz A
    Prostate; 2003 Mar; 54(4):275-89. PubMed ID: 12539226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
    Yoda T; Kikuchi K; Miki Y; Onodera Y; Hata S; Takagi K; Nakamura Y; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H; McNamara KM
    Mol Cell Endocrinol; 2015 Sep; 413():236-47. PubMed ID: 26170067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
    Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
    Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells.
    Rizner TL; Lin HK; Penning TM
    Chem Biol Interact; 2003 Feb; 143-144():401-9. PubMed ID: 12604227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
    Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
    Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
    Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2α biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
    Sinreih M; Anko M; Kene NH; Kocbek V; Rižner TL
    Chem Biol Interact; 2015 Jun; 234():320-31. PubMed ID: 25446850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.